| Literature DB >> 31678385 |
Rayan Sabra1, Nashiru Billa2, Clive J Roberts3.
Abstract
In the present study, we successfully developed a cetuximab-conjugated modified citrus pectin-chitosan nanoparticles for targeted delivery of curcumin (Cet-MCPCNPs) for the treatment of colorectal cancer. In vitro analyses revealed that nanoparticles were spherical with size of 249.33 ± 5.15 nm, a decent encapsulation efficiency (68.43 ± 2.4%) and a 'smart' drug release profile. 61.37 ± 0.70% of cetuximab was adsorbed to the surface of the nanoparticles. Cellular uptake studies displayed enhanced internalization of Cet-MCPCNPs in Caco-2 (EGFR +ve) cells, which ultimately resulted in a significant reduction in cancer cell propagation. The cell cycle analysis indicated that Cet- MCPCNPs induced cell death in enhanced percentage of Caco-2 cells by undergoing cell cycle arrest in the G2/M phase. These data suggest that Cet-MCPCNPs represent a new and promising targeting approach for the treatment of colorectal cancer.Entities:
Keywords: Cetuximab; Chitosan; Colorectal cancer; Curcumin; Modified citrus pectin; Targeted delivery
Mesh：
Substances：
Year: 2019 PMID： 31678385 DOI： 10.1016/j.ijpharm.2019.118775
Source DB: PubMed Journal: Int J Pharm ISSN： 0378-5173 Impact factor: 5.875